ADC Therapeutics SA
NYSE:ADCT
EV/S
Enterprise Value to Sales
Enterprise Value to Sales (EV/S) ratio is a valuation multiple that compares the enterprise value (EV) of a company to its revenues. The EV/S multiple gives investors a quantifiable metric of how to value a company based on its sales while taking account of both the company's equity and debt.
EV/S History
Statistics
Enterprise Value to Sales
1 Year | 3 Years | 5 Years | |
---|---|---|---|
Average | 2.5 | 48.5 | 29.4 |
Median | 1.7 | 1.4 | N/A |
Min | 0.9 | N/A | N/A |
Max | 6.2 | 523.9 | 523.9 |
History Chart
Enterprise Value to Sales
EV/S Forward Multiples
Forward EV/S multiple is a version of the EV/S ratio that uses forecasted revenue for the EV/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
EV/S Across Competitors
ADCT Competitors
ADC Therapeutics SA Competitors
Market Cap | EV/S | ||||
---|---|---|---|---|---|
CH |
A
|
ADC Therapeutics SA
NYSE:ADCT
|
190M USD | 1.1 | |
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
243B USD | 5.2 | |
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
118B USD | 5.6 | |
AU |
![]() |
CSL Ltd
ASX:CSL
|
148B AUD | 9 | |
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
96B USD | 4.2 | |
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
83.3B USD | 8 | |
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.7B USD | 6 | |
US |
![]() |
Moderna Inc
NASDAQ:MRNA
|
49B USD | 2.7 | |
US |
![]() |
Biogen Inc
NASDAQ:BIIB
|
42.9B USD | 4.4 | |
US |
![]() |
Seagen Inc
NASDAQ:SGEN
|
36.7B USD | 17.1 | |
DK |
![]() |
Genmab A/S
NASDAQ:GMAB
|
25.9B USD | 10.2 |
EV/S Multiple | Earnings Growth | |||
---|---|---|---|---|
CH |
A
|
ADC Therapeutics SA
NYSE:ADCT
|
1.1
|
-17%
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
5.2
|
-3%
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
5.6
|
10%
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
9
|
59%
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
4.2
|
5%
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
8
|
29%
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
6
|
19%
|
US |
![]() |
Moderna Inc
NASDAQ:MRNA
|
2.7
|
-63%
|
US |
![]() |
Biogen Inc
NASDAQ:BIIB
|
4.4
|
-4%
|
US |
![]() |
Seagen Inc
NASDAQ:SGEN
|
17.1
|
113%
|
DK |
![]() |
Genmab A/S
NASDAQ:GMAB
|
10.2
|
56%
|
Relative Valuation Report
View full relative valuation report for ADC Therapeutics SA, which takes into account all ADCT`s valuation multiples.